Celldex Therapeutics Inc., the Needham company developing a brain cancer vaccine, has priced a public offering of 10 million shares of its common stock (Nasdaq: CLDX) at about $3.15 per share. The offering would raise $31.5 million, with Celldex taking in about $29.4 million in net proceeds.
Celldex noted in a news release today that it plans to use the proceeds from the stock offering to support clinical trials of its products and to add to its working capital.
SOURCE
